Exponential Biotherapies, Inc. – Trademark Portfolio
Entity Type: 03
Exponential Biotherapies, Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EBI EXPONENTIAL BIOTHERAPIES. The owner is based in New York, NY.
19 W. 34th Street, Penthouse
New York, NY 10001
Showing of trademarks Trademarks
Trademark Classifications
Exponential Biotherapies, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Exponential Biotherapies, Inc. have?
Exponential Biotherapies, Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.
What trademark classes does Exponential Biotherapies, Inc. file in?
Exponential Biotherapies, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Exponential Biotherapies, Inc.'s most well-known trademarks?
Exponential Biotherapies, Inc.'s registered trademark portfolio includes well-known marks such as EBI EXPONENTIAL BIOTHERAPIES. These are among 1 currently registered trademark in the portfolio.
What is Exponential Biotherapies, Inc.'s trademark registration success rate?
Exponential Biotherapies, Inc. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.